RecruitingNot ApplicableNCT06388148

Endovascular Treatment for eXtra-Large Ischemic Stroke

Efficacy and Safety of Endovascular Thrombectomy Plus Medical Management Versus Medical Management Alone in Acute Ischemic Stroke Patients With Large Vessel Occlusion and Extra-Large Infarct Core: A Multicenter, Randomized Controlled Trial


Sponsor

Zhongming Qiu

Enrollment

286 participants

Start Date

Jun 16, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlusion.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older;
  • Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \> 6 hours or unknown last known well time;
  • Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA/MRA/DSA;
  • Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml;
  • The patient or patient's representative signs a written informed consent form.

Exclusion Criteria6

  • CT or MR evidence of hemorrhage;
  • Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;
  • Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access;
  • History of bleeding disorders, severe heart, liver or kidney disease, or sepsis;
  • Currently participating in another investigational drug study;
  • Any terminal illness with life expectancy less than 6 months.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMedical management

Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.

PROCEDUREEndovascular thrombectomy

Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.


Locations(2)

The First Affiliated Hospital, Hengyang Medical School, University of South China

Hengyang, Hunan, China

Xiangtan Central Hospital

Xiangtan, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06388148


Related Trials